Molecular Imaging of the Tumor Microenvironment

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 681

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan
Interests: biomolecular imaging; biology; molecular diagnostics; tumor metabolism; tumor immune microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

With the progress in research, we all acknowledge that treating cancer involves focusing on cancer cells and understanding their interactions with the surrounding cells and extracellular matrix, which compose the tumor microenvironments (TME). Immunotherapies have recently shown promising results in various types of cancers, and the concept of the tumor microenvironment has expanded to include immune-related components such as immune cells and cytokines. Consequently, a new field of research called the tumor immune microenvironment (TIME) has been proposed and actively explored.

Traditionally, many animals have to be used to study specific events occurring in the TME/TIME because they need to be sacrificed to conduct different experiments. However, with the emergence and utilization of molecular imaging in biomedical research, disease progression and interactions between multiple cell types or overall tumor microenvironmental changes can be tracked employing various imaging instruments noninvasively at multiple time points using the same cohort of animals.

We welcome original research articles, editorials and review articles.

Dr. Hui-Yen Chuang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular imaging
  • radiopharmaceuticals
  • tumor microenvironment
  • immune microenvironment
  • angiogenesis
  • pH sensors
  • theranostics
  • nanoparticles
  • drug delivery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 5155 KiB  
Article
Characterization and Comparison of Contrast Imaging Properties of Naturally Isolated and Heterologously Expressed Gas Vesicles
by Tingting Liu, Jieqiong Wang, Chenxing Liu, Yuanyuan Wang, Zhenzhou Li and Fei Yan
Pharmaceuticals 2024, 17(6), 755; https://doi.org/10.3390/ph17060755 - 7 Jun 2024
Viewed by 509
Abstract
Nanoscale ultrasound contrast agents have attracted considerable interest in the medical imaging field for their ability to penetrate tumor vasculature and enable targeted imaging of cancer cells by attaching to tumor-specific ligands. Despite their potential, traditional chemically synthesized contrast agents face challenges related [...] Read more.
Nanoscale ultrasound contrast agents have attracted considerable interest in the medical imaging field for their ability to penetrate tumor vasculature and enable targeted imaging of cancer cells by attaching to tumor-specific ligands. Despite their potential, traditional chemically synthesized contrast agents face challenges related to complex synthesis, poor biocompatibility, and inconsistent imaging due to non-uniform particle sizes. To address these limitations, bio-synthesized nanoscale ultrasound contrast agents have been proposed as a viable alternative, offering advantages such as enhanced biocompatibility, consistent particle size for reliable imaging, and the potential for precise functionalization to improve tumor targeting. In this study, we successfully isolated cylindrical gas vesicles (GVs) from Serratia. 39006 and subsequently introduced the GVs-encoding gene cluster into Escherichia coli using genetic engineering techniques. We then characterized the contrast imaging properties of two kinds of purified GVs, using in vitro and in vivo methods. Our results demonstrated that naturally isolated GVs could produce stable ultrasound contrast signals in murine livers and tumors using clinical diagnostic ultrasound equipment. Additionally, heterologously expressed GVs from gene-engineered bacteria also exhibited good ultrasound contrast performance. Thus, our study presents favorable support for the application of genetic engineering techniques in the modification of gas vesicles for future biomedical practice. Full article
(This article belongs to the Special Issue Molecular Imaging of the Tumor Microenvironment)
Show Figures

Figure 1

Back to TopTop